IQM, Europe's first public quantum company, admits the future of the tech is uncertain

Let’s be clear about what happened Thursday: Europe’s quantum champion went public in New York and the market yawned. IQM’s SPAC merger valued the Finnish full-stack player at $1.9 billion, but shares traded below the offer price all day. That’s not a debut; it’s a shrug.

The real story isn’t the lukewarm reception. It’s the prospectus. Buried in the fine print, IQM admitted something the entire industry whispers but rarely shouts: “large-scale commercial traction of quantum computing technology may never occur.” Read that again. A company building quantum computers just told investors the market might never materialize.

Honesty as a strategy

There’s a perverse integrity to it. Most quantum startups sell inevitability — roadmaps bending toward “quantum advantage” like hockey sticks. IQM, to its credit, sold reality. The warning applies to every player in the space: Rigetti, IonQ, PsiQuantum, the lot. But saying it out loud while ringing the bell? That’s either radical transparency or a liability shield. Probably both.

And yet, the business exists. Twenty-two customers in 2025, up from eight a year ago. Two from the private sector. They’re selling physical systems to supercomputing centers — VTT in Finland, Leibniz in Germany — and cloud time to anyone with a budget and a problem. That’s revenue. That’s traction. It’s just not commercial traction in the sense Wall Street understands: recurring, scalable, predictable.

The advantage that never arrives

“Quantum advantage” remains the industry’s Godot. The moment quantum chips outperform classical ones on useful problems — drug discovery, portfolio optimization, breaking RSA — the dam breaks. Valuations justify themselves. Until then, it’s R&D masquerading as product.

IQM’s CEO Jan Goetz puts it plainly: “We sell computers into advanced supercomputing centers and data centers, and we sell computing time through the cloud.” Notice the customer set. National labs. Research institutes. Not banks. Not pharma. Not logistics giants. The buyers are the same people funding the science. That’s a closed loop, not a market.

Trump’s quantum bet

Enter the political tailwind. The Trump administration’s executive orders accelerating quantum timelines — and the DOE’s pledge to deploy a “fault-tolerant, scientifically relevant quantum computer” by 2028 — changed the conversation. IQM, with its Maryland tech center and Oak Ridge deployment, positions itself as a direct beneficiary. Goetz didn’t mince words: “We can benefit directly from it.”

This is where the editorializing gets uncomfortable. The U.S. is treating quantum as a national security imperative — encryption, simulation, supremacy. Europe talks sovereignty but writes checks an order of magnitude smaller. IQM straddles both: listed on Nasdaq (ticker IQMX) for American capital, listing on Nasdaq Helsinki tomorrow for Finnish state support via Tesi, the sovereign wealth fund. It’s a dual-track strategy that reveals the continent’s dilemma: build here, exit there.

Finland’s unlikely champion

IQM’s story is inseparable from Espoo. Spun out of Aalto University in 2018, two-thirds of its 420-person team still works within walking distance of the campus where the science happened. Another hundred sit in Munich. The rest scatter across deployment sites. This isn’t a Delaware C-corp with a European mailing address. It’s a Finnish company that grew up in the open, funded by European deep-tech funds and the EIC, now carrying the flag for a continent desperate for hard-tech wins.

But the prospectus — truncated in the source — likely details the same risks every quantum prospectus does: decoherence, error correction, talent wars, supply chain fragility, the possibility that a different modality (photonics, neutral atoms, topological qubits) leapfrogs superconducting circuits. IQM bets on superconducting. So does Google. So does IBM. Consensus isn’t conviction.

The SPAC stigma

Let’s not ignore the vehicle. SPAC mergers carry a stigma retail investors have learned to punish. The structure incentivizes promoters to get deals done, not to get good deals done. IQM’s choice reflects limited options: European public markets don’t swallow $2B deep-tech bets with zero profitability visibility. The U.S. does — sometimes. But the SPAC route signals urgency, not strength.

Thursday’s price action confirmed the skepticism. Shares below $10. No pop. No momentum. Just a quiet acknowledgment that the emperor’s new qubits might never clothe a real business.

What happens next

IQM will deploy the SPAC proceeds — roughly €200 million net — into scaling manufacturing, hiring, and the U.S. footprint. It will chase DOE contracts. It will announce more supercomputing center wins. Revenue will grow. Losses will deepen. And in 2028, when the DOE’s fault-tolerant deadline arrives, we’ll find out if the industry delivered or just moved the goalposts again.

Until then, IQM is a research institute with a ticker symbol. That’s not an insult. It’s a description. The market priced it accordingly. The only uncertainty is whether honesty about uncertainty counts as a competitive advantage — or just a warning label investors actually read.